



BT07 Rec'd PCT/PTO 10 MAR 2003

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Application Number	10/009,508
Filing Date	November 6, 2001
First Named Inventor	Su, Sai L.
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	020093-001000US
Total Number of Pages in This Submission	1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449; References AA- BG; Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Brian W. Poor	Reg. No. 32,928
Signature		
Date	5 March 2003	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: Mar. 5, 2003

Typed or printed	Jennifer M. Smolen		
Signature		Date	Mar. 5, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

#9

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on Mar. 5, 2003

By: J. M. J. J.

PATENT
Attorney Docket No. 020093-001000US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Sai L. SU

Application No.: 10/009,508

Filed: November 6, 2001

For: METHODS FOR THE DIAGNOSIS
AND TREATMENT OF
METASTATIC PROSTATE
TUMORS

Examiner: Not assigned

Art Unit: Not assigned

**INFORMATION DISCLOSURE
STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants direct the Examiner's attention to the references below, also listed on the accompanying Form PTO-1449. A copy of each is also enclosed.

The following articles are set forth in alphabetical order:

AA. Achen *et al.*, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," *Proc. Natl. Acad. Sci. USA* 95:548-553 (1998)

AB. Bigler *et al.*, "Comparison of microscopic vascularity in benign and malignant prostate tissue," *Hum. Pathol.* 24:220-226 (1993)

AC. Brawer *et al.*, "Predictors of pathologic stage in prostatic carcinoma," *Cancer* 73:678-687 (1994)

AD. Brown *et al.*, "Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen," *J. Urol.* 154:576-579 (1995)

AE. Chevalier, "This month in investigative urology: Commentary on prostatic neovascularization and vascular endothelial growth factor," *J. Urol.* 157:2040-2041 (1997)

AF. Connolly *et al.*, "Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice," *J. Urol.* 160:932-936 (1998)

AG. Deering *et al.*, "Microvascularity in benign prostatic hyperplasia," *Prostate* 26:111-115 (1995)

AH. Ferrara *et al.*, "The vascular endothelial growth factor family of polypeptides," *J. Cell Biochem.* 47:211-8 (1991)

AI. Ferrara, "The role of vascular endothelial growth factor in pathological angiogenesis," *Breast Cancer Res. Treat.* 36:127-137 (1995)

AJ. Ferrer *et al.*, "Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells," *J. Urol.* 157:2329-2333 (1997)

AK. Ferrer *et al.*, "Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells," *Urology* 51:161-167 (1998)

AL. Frank *et al.*, "Regulation of vascular endothelial growth factor expression in cultured keratinocytes," *J. Biol. Chem.* 270:12607-12613 (1995)

AM. Furusato *et al.*, "Tumour angiogenesis in latent prostatic carcinoma," *Br. J. Cancer* 70:1244-1246 (1994)

AN. Galland *et al.*, "Chromosomal localization of *FLT4*, a Novel Receptor-Type Tyrosine Kinase Gene," *Genomics* 13:475-478 (1992)

AO. Gitay-Goren *et al.*, "Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors," *Biochem. Biophys. Res. Commun.* 190:702-709 (1993)

AP. Harper *et al.*, "Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells," *Br. J. Cancer* 74:910-916 (1996)

AQ. Jackson *et al.*, "Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia," *J. Urol.* 157:2323-2328 (1997)

AR. Jeltsch *et al.*, "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice," *Science* 276:1423-1425 (1997)

AS. Joukov *et al.*, "Vascular endothelial growth factors VEGF-B and VEGF-C," *J. Cell Physiol.* 173:211-215 (1997)

AT. Joukov *et al.*, "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," *EMBO J.* 15:290-298 (1996)

AU. Joukov *et al.*, "Proteolytic processing regulates receptor specificity and activity of VEGF-C," *EMBO J.* 16:3898-3911 (1997)

AV. Kaipainen *et al.*, *J. Exp. Med.* 178:2077-2088 (1993) [waiting for]

AW. Kaipainen *et al.*, "Expression of the *fms*-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development," *Proc. Natl. Acad. Sci. USA* 92:3566-3570 (1995)

AX. Klagsbrun *et al.*, "Vascular endothelial growth factor and its receptors," *Cytokine & Growth Factor Rev.* 7:259-270 (1996)

AY. Lymboussaki *et al.*, "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," *Am. J. Pathol.* 153:395-403 (1998)

AZ. Moustonen *et al.*, "Endothelial receptor tyrosine kinases involved in angiogenesis," *J. Cell Biol.* 129:895-898(1995)

BA. Oh *et al.*, "VEGF and VEGF-C: Specific Induction of Angiogenesis and Lymphangiogenesis in the Differentiated Avian Chorioallantoic Membrane," *Dev. Biol.* 188:96-109 (1997)

BB. Shibuya, "Role of VEGF-FLT receptor system in normal and tumor angiogenesis," *Adv. Cancer Res.* 67:281-316 (1995)

BC. Shweiki *et al.*, "Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis," *J. Clin. Invest.* 91:2235-2243 (1993)

BD. Siegal *et al.*, "Topography of neovascularity in human prostate carcinoma," *Cancer* 75:2545-2451 (1995)

BE. Weidner *et al.*, "Tumoral vascularity as a prognostic factor in cancer," *Important Adv. Oncol.* 167-190 (1996)

BF. Woessner *et al.*, "Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium," *Exp. Mol. Pathol.* 65:37-52 (1998)

BG. Yamada *et al.*, "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D," *Genomics* 42:483-488 (1997)

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant believes that his invention as claimed is patentable over the above references taken alone or in any combination. However, Applicant reserves the right to demonstrate that his claimed invention was made prior to any one or more of the above-identified references. No inference should be drawn as to the pertinence of the references based on the order in which they are presented.

Applicant respectfully requests that the Examiner review the foregoing references to make his own determination of the patentability of the present invention and that the references be made of record in the file of this application.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Dated: 5 March 2003

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111
Tel.: (206) 467-9600
Fax: (415) 576-0300



FORM PTO-1449 (Modified)		Attorney Docket No.: 020093-001000US		Application No.: 10/009,508			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sai L. SU					
		Filing Date: Nov. 6, 2001		Group: Not assigned			
Reference Designation		U.S. PATENT DOCUMENTS			Page 1 of 1		
Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AA	Achen <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. USA</i> 95:548-553 (1998)					
	AB	Bigler <i>et al.</i> , "Comparison of microscopic vascularity in benign and malignant prostate tissue," <i>Hum. Pathol.</i> 24:220-226 (1993)					
	AC	Brawer <i>et al.</i> , "Predictors of pathologic stage in prostatic carcinoma," <i>Cancer</i> 73:678-687 (1994)					
	AD	Brown <i>et al.</i> , "Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen," <i>J. Urol.</i> 154:576-579 (1995)					
	AE	Chevalier, "This month in investigative urology: Commentary on prostatic neovascularization and vascular endothelial growth factor," <i>J. Urol.</i> 157:2040-2041 (1997)					
	AF	Connolly <i>et al.</i> , "Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice," <i>J. Urol.</i> 160:932-936 (1998)					
	AG	Deering <i>et al.</i> , "Microvasculature in benign prostatic hyperplasia," <i>Prostate</i> 26:111-115 (1995)					
	AH	Ferrara <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cell Biochem.</i> 47:211-8 (1991)					
	AI	Ferrara, "The role of vascular endothelial growth factor in pathological angiogenesis," <i>Breast Cancer Res. Treat.</i> 36:127-137 (1995)					
	AJ	Ferrer <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells," <i>J. Urol.</i> 157:2329-2333 (1997)					
	AK	Ferrer <i>et al.</i> , "Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells," <i>Urology</i> 51:161-167 (1998)					
	AL	Frank <i>et al.</i> , "Regulation of vascular endothelial growth factor expression in cultured keratinocytes," <i>J. Biol. Chem.</i> 270:12607-12613 (1995)					
	AM	Furusato <i>et al.</i> , "Tumour angiogenesis in latent prostatic carcinoma," <i>Br. J. Cancer</i> 70:1244-1246 (1994)					
	AN	Galland <i>et al.</i> , "Chromosomal localization of <i>FLT4</i> , a Novel Receptor-Type Tyrosine Kinase Gene," <i>Genomics</i> 13:475-478 (1992)					
	AO	Gitay-Goren <i>et al.</i> , "Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors," <i>Biochem. Biophys. Res. Commun.</i> 190:702-709 (1993)					
	AP	Harper <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells," <i>Br. J. Cancer</i> 74:910-916 (1996)					
	AQ	Jackson <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia," <i>J. Urol.</i> 157:2323-2328 (1997)					
	AR	Jeltsch <i>et al.</i> , "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice," <i>Science</i> 276:1423-1425 (1997)					
	AS	Joukov <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15:290-298 (1996)					

